Promising cancer drug from BioNTech

BioNTech announced that its targeted drug, codenamed BNT323, is in phase 3 testing and is effective in slowing down HER2-positive breast cancer, which is no longer surgically treatable. Özlem Türeci, one of BionTech 's co-founders, described the development as a milestone. This study marks BioNTech's first major success among its advanced-stage oncology programs. BioNTech and its Chinese partner, Duality Biologics (dualiti bayolociks), announced plans to develop the drug outside of China. A release date for the drug is currently unknown. Efforts are underway to secure approval in countries outside of China.